Citi analyst Yigal Nochomovitz raised the firm’s price target on Arcturus Therapeutics (ARCT) to $8 from $7 and keeps a Neutral rating on the shares. The company said during its Q4 call that ARCT-032’s third cohort has not encountered any safety and tolerability concerns, the analyst tells investors in a research note. Citi remains cautious, however.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics reports Q4 EPS ($1.03), consensus (76c)
- Options Volatility and Implied Earnings Moves Today, March 03, 2026
- ARCT Earnings this Week: How Will it Perform?
- Arcturus’ ARCT-2304 Flu Vaccine Trial Reaches Phase 1 Finish Line: What Investors Should Watch Next
- Arcturus Therapeutics initiated with a Buy at Roth Capital